Division of Cardiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
JAMA Cardiol. 2022 Oct 1;7(10):1027-1035. doi: 10.1001/jamacardio.2022.2825.
Women have a lower incidence of atrial fibrillation (AF) compared with men in several studies, but it is unclear whether this sex difference is independent of sex differences in prevalent cardiovascular disease (CVD), body size, and other risk factors.
To examine sex differences in AF incidence and whether AF risk factors differ by sex in a contemporary cohort of men and women without prevalent CVD.
DESIGN, SETTING, AND PARTICIPANTS: This was a prospective cohort analysis within the Vitamin D and Omega-3 Trial (VITAL) Rhythm Study, a randomized trial that examined the effect of vitamin D and ω-3 fatty acid supplementation on incident AF among men 50 years or older and women 55 years or older without a prior history of prevalent AF, CVD, or cancer at baseline. Data were analyzed from September 29, 2020, to June 29, 2021.
Sex, height, weight, body mass index (BMI), body surface area (BSA), and other AF risk factors at study enrollment.
Incident AF confirmed by medical record review.
A total of 25 119 individuals (mean [SD] age, 67.0 [7.1] years; 12 757 women [51%]) were included in this study. Over a median (IQR) follow-up of 5.3 (5.1-5.7) years, 900 confirmed incident AF events occurred among 12 362 men (495 events, 4.0%) and 12 757 women (405 events, 3.2%). After adjustment for age and treatment assignment, women were at lower risk for incident AF than men (hazard ratio [HR], 0.68; 95% CI, 0.59-0.77; P < .001). The inverse association between female sex and AF persisted after adjustment for race and ethnicity, smoking, alcohol intake, hypertension, diabetes (type 1, type 2, gestational), thyroid disease, exercise, and BMI (HR, 0.73; 95% CI, 0.63-0.85; P <.001). However, female sex was positively associated with AF when height (HR, 1.39; 95% CI, 1.14-1.72; P = .001), height and weight (HR 1.49, 95% CI, 1.21-1.82; P <.001), or BSA (HR, 1.25; 95% CI, 1.06-1.49; P = .009) were substituted for BMI in the multivariate model. In stratified models, risk factor associations with incident AF were similar for women and men.
In this cohort study, findings suggest that after controlling for height and/or body size, women without CVD at baseline were at higher risk for AF than men, suggesting that sex differences in body size account for much of the protective association between female sex and AF. These data underscore the importance of AF prevention in women.
在几项研究中,女性的房颤(AF)发病率低于男性,但尚不清楚这种性别差异是否独立于心血管疾病(CVD)、身体大小和其他风险因素的性别差异。
在没有 CVD 前期的男性和女性当代队列中,检查 AF 发病率的性别差异,以及 AF 风险因素是否因性别而异。
设计、地点和参与者:这是维生素 D 和 ω-3 试验(VITAL)节律研究的一项前瞻性队列分析,该研究是一项随机试验,研究了维生素 D 和 ω-3 脂肪酸补充剂对基线时无 CVD 前期史、AF 或癌症的 50 岁及以上男性和 55 岁及以上女性的 AF 发病率的影响。数据于 2020 年 9 月 29 日至 2021 年 6 月 29 日进行分析。
性别、身高、体重、体重指数(BMI)、体表面积(BSA)和其他 AF 风险因素在研究入组时。
通过病历回顾确认的 AF 发生率。
共有 25119 人(平均[标准差]年龄,67.0[7.1]岁;12757 名女性[51%])纳入本研究。在中位数(IQR)随访 5.3(5.1-5.7)年后,12362 名男性中有 900 例经证实的 AF 事件(495 例,4.0%),12757 名女性中有 12757 例(405 例,3.2%)。在调整年龄和治疗分配后,女性的 AF 发病风险低于男性(风险比[HR],0.68;95%CI,0.59-0.77;P<.001)。在调整种族和民族、吸烟、饮酒、高血压、糖尿病(1 型、2 型、妊娠期)、甲状腺疾病、运动和 BMI 后,女性性别与 AF 之间的负相关仍然存在(HR,0.73;95%CI,0.63-0.85;P<.001)。然而,当身高(HR,1.39;95%CI,1.14-1.72;P=.001)、身高和体重(HR 1.49,95%CI,1.21-1.82;P<.001)或 BSA(HR,1.25;95%CI,1.06-1.49;P=.009)替代 BMI 时,女性性别与 AF 呈正相关多变量模型。在分层模型中,女性和男性的风险因素与 AF 发生率的相关性相似。
在这项队列研究中,研究结果表明,在控制身高和/或身体大小后,基线时无 CVD 的女性发生 AF 的风险高于男性,这表明女性身体大小的性别差异在很大程度上解释了女性性别与 AF 之间的保护关联。这些数据强调了预防 AF 在女性中的重要性。